Cutaneous toxicities of targeted cancer therapies

Community Oncology

Volumn 5, Issue 7, 2008, Pages 413-414

  Lacouture, Mario E ^a   West, Dennis P ^a   Tigue, Cara C ^a   Knox, Kjersti ^a   Bennett, Charles L ^a,b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LIDOCAINE; PRAMOCAINE; PREGABALIN; SORAFENIB; STEROID; TETRACYCLINE;

ACNE; ACTINIC KERATOSIS; ALOPECIA; ARTICLE; BACTERIAL INFECTION; CANCER THERAPY; FOLLICULITIS; HAIR FOLLICLE; HEAD LESION; HUMAN; INFLAMMATION; KIDNEY CARCINOMA; MACULOPAPULAR RASH; MOUTH ULCER; NAIL INFLAMMATION; NOSE MUCOSA; PAPULAR RASH; PARONYCHIA; PRURITUS; RASH; SCALP ALOPECIA; SIDE EFFECT; SKIN DEFECT; SKIN PAIN; SQUAMOUS CELL CARCINOMA; XEROSIS;

EID: 48749129058     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70476-4     Document Type: Article

References (4)

1. O'Keeffe P, Parrilli M, Lacouture ME. Toxicity of targeted therapy: focus on rash and other dermatologic side effects. Oncol Nurse Ed 2006;20(103 suppl):l-6.
2. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812.
3. Lacouture ME, Desai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006;31:783-785.
4. Lacouture ME, Basti S, Patel J, Benson A 3rd. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 2006;4:236-238.